E
Ebenezer Daniel
Researcher at University of Pennsylvania
Publications - 193
Citations - 6983
Ebenezer Daniel is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Macular degeneration & Visual acuity. The author has an hindex of 40, co-authored 180 publications receiving 5597 citations. Previous affiliations of Ebenezer Daniel include Vignan University & Karunya University.
Papers
More filters
Journal ArticleDOI
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
Juan E. Grunwald,Ebenezer Daniel,Jiayan Huang,Gui-Shuang Ying,Maureen G. Maguire,Cynthia A. Toth,Glenn J. Jaffe,Stuart L. Fine,Barbara A Blodi,Michael L. Klein,Alison Martin,Stephanie A. Hagstrom,Daniel F. Martin +12 more
TL;DR: Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography were evaluated as risk factors for GA through 2 years of follow-up and found no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.
Journal ArticleDOI
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials
Maureen G. Maguire,Daniel F. Martin,Gui-Shuang Ying,Glenn J. Jaffe,Ebenezer Daniel,Juan E. Grunwald,Cynthia A. Toth,Frederick L. Ferris,Stuart L. Fine +8 more
TL;DR: Vision gains during the first 2 years were not maintained, but 50% of eyes had VA of 20/40 or better, confirming anti-vascular endothelial growth factor therapy as a major long-term therapeutic advance for neovascular AMD.
Journal ArticleDOI
Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
Gui-Shuang Ying,Jiayan Huang,Maureen G. Maguire,Glenn J. Jaffe,Juan E. Grunwald,Cynthia A. Toth,Ebenezer Daniel,Michael L. Klein,Dante J. Pieramici,John A. Wells,Daniel F. Martin +10 more
TL;DR: In this paper, the baseline predictors of visual acuity (VA) outcomes 1 year after treatment with ranibizumab or bevacizumaab for neovascular age-related macular degeneration (AMD) were determined using regression techniques.
Journal ArticleDOI
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
Glenn J. Jaffe,Daniel F. Martin,Cynthia A. Toth,Ebenezer Daniel,Maureen G. Maguire,Gui-Shuang Ying,Juan E. Grunwald,Jiayan Huang +7 more
TL;DR: Anti-vascular endothelial growth factor (VEGF) therapy reduced lesion activity and improved VA in all treatment groups, and these results have important treatment implications in eyes undergoing anti-VEGF therapy for neovascular AMD.
Journal ArticleDOI
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Ebenezer Daniel,Cynthia A. Toth,Juan E. Grunwald,Glenn J. Jaffe,Daniel F. Martin,Stuart L. Fine,Jiayan Huang,Gui-Shuang Ying,Stephanie A. Hagstrom,Katrina P. Winter,Maureen G. Maguire +10 more
TL;DR: Nearly half of eyes enrolled in CATT developed scar by 2 years, with classic neovascularization, a thicker retina, and more fluid or material under the foveal center of the retina are more likely to develop scar.